NEW YORK – Finnish diagnostics firm Nightingale Health said Wednesday that it has closed an €8.8 million ($10.7 million) funding round.
The company said that the funding will strengthen its working capital as it investigates the possibility of listing its shares on the Nasdaq First North Growth Market.
Finnish private investors contributed to the round including Timo Soininen, the chairman of Nightingale's board; Markku Kaloniemi; Mikko Kodisoja; the Langenskiöld family investment firm; and Leena Niemistö.
Nightingale also announced that it has appointed Niemistö to its board of directors.
The company offers a direct-to-consumer wellness blood testing service in the Helsinki area as well as blood and urine biomarker research services. It uses nuclear magnetic resonance spectroscopy for metabolite testing.